Pfizer: The Rally May Just Be Getting Started

no_limit_pictures Intro & Thesis I reinitiated my coverage of Pfizer Inc. (NYSE:PFE) stock at the end of December 2023 with a "Buy" rating, when the stock was trading at $27.86 apiece. Since then, I have published 3 more articles, which, ultimately, have proven effective in terms of relative and absolute performance: PFE's total return outpaced the S&P 500 index (SP500) (SPX) quite meaningfully. The index has remained stagnant, hovering around 0% over the past 3 months, while PFE gave a total return of over ...